Immunogenicity of the <scp>BNT162b2 mRNA</scp> vaccine in heart transplant <scp>recipients – a</scp> prospective cohort study

Abstract

The generally achieved protection from SARS-CoV-2 mRNA vaccination should be regarded with caution in the population of HTx recipients. The possible benefit of additive vaccine should be further studied.